Dr. Matthew Galsky interprets latest atezolizumab/chemo results in bladder cancer
Galsky highlights final OS data from the IMvigor130 trial, along with an exploratory analysis examining outcomes by type of chemotherapy used.
Related Articles
Anne Schuckman, MD, highlights promising new developments in NMIBC
Anne Schuckman, MD, on optimal sequencing strategies, the SWOG 1602 trial, and the emerging role of ctDNA.
Live Events
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC
The phase 1 study is set to begin later this year.
CHMP recommends EU approval of darolutamide plus ADT in mHSPC
The approval is supported by data from the pivotal phase 3 ARANOTE trial.
Amir Patel, MD, on onabotulinumtoxinA injection at the time of HoLEP
Amir S. Patel, MD, discusses interim findings from a randomized controlled trial of onabotulinumtoxinA injection at the time of HoLEP vs standard treatment.
Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
The conversation covers practical, case-based strategies for counseling MSM patients.
FDA approves label expansion for Rezūm Water Vapor Thermal Therapy for BPH
The approval is supported by several studies highlighting the efficacy of Rezūm Water Vapor Therapy in patients with larger prostates,
Howard Goldman, MD, discusses development of the Glean Urodynamics System
Howard B. Goldman, MD, discusses the rationale and development process for the Glean Urodynamics System.
Data link incontinence severity to post-radical prostatectomy care
The investigators found a clear, dose-response relationship between patient-reported incontinence severity and the subsequent use of incontinence interventions such as artificial sphincters or bulking agents.
Real-world studies compare overall survival between ARPIs in mCSPC
“Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with…